Two-Drug combo aims to shrink head and neck tumors before surgery
NCT ID NCT07677475
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding MRG003 (a targeted drug) to toripalimab (an immunotherapy) before surgery can shrink tumors more than toripalimab alone in people with PD-L1-positive, locally advanced head and neck cancer. Participants receive two cycles of either the combination or toripalimab alone, followed by surgery and additional therapy. The main goal is to see how many patients have a major reduction in tumor cells after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MRG003 (becotatug vedotin) and toripalimab
What this could lead to
If successful, this combination could shrink tumors more effectively before surgery, potentially improving long-term outcomes for people with head and neck cancer.
What could go wrong
This is an early-phase trial with a small number of participants. The combination may not prove better than toripalimab alone, and side effects from the two drugs could be more severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Tenth Affiliated Hospital of Southern Medical University (Dongguan People's Hospital)
Dongguan, Guangdong, 523059, China
Contact Phone: •••-•••-•••• Email: •••••@•••••